



*cancers*



an Open Access Journal by MDPI

## Concepts to Improve Targeted Radionuclide Therapy in Cancer: Ligand Design Optimization and Application of Emerging Radionuclides and Combination Therapies

Guest Editor:

**Prof. Dr. Cristina Müller**

Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen-PSI, and ETH Zurich, Department of Chemistry and Applied Biosciences, 8093 Zurich, Switzerland

Deadline for manuscript submissions:

**30 June 2024**

### Message from the Guest Editor

Dear Colleagues,

The field of nuclear oncology has become increasingly important in cancer therapy mainly due to the successful application of peptide-receptor radionuclide therapy using somatostatin analogues and PSMA ligand-based radioligand therapy.

It will thus be of paramount interest to develop innovative concepts of novel radionuclide therapies and improve existing ones to allow a broader range of applications. The goal of this Special Issue is to present a collection of research studies describing ligand design optimization (e.g., through linker modification or the use of albumin binders or cleavable linkers) as well as the application of nonstandard radionuclides (e.g., alpha-particle/Auger electron emitters) and investigations of combination therapies.

I am pleased to invite you to contribute to this Special Issue “Concepts to Improve Targeted Radionuclide Therapy in Cancer: Ligand Design Optimization and Application of Emerging Radionuclides and Combination Therapies”. Original research articles and communications as well as review articles are welcome.

We look forward to receiving your contributions.

Prof. Dr. Cristina Müller  
*Guest Editor*



[mdpi.com/si/125816](https://mdpi.com/si/125816)

# Special Issue



# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI